American Association for Cancer Research
10780432ccr210133-sup-258815_2_supp_6958546_qpcq8n.docx (44.74 kB)

Supplementary fig 1 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Download (44.74 kB)
journal contribution
posted on 2023-03-31, 22:29 authored by Chunmeng Wang, Yang Liu, Liang Dong, Xiang Li, Qingming Yang, Malcolm V. Brock, Qian Mei, Jiejie Liu, Meixia Chen, Fengxia Shi, Miao Liu, Jing Nie, Weidong Han

Figure 1. Anti-tumor response.


This work was supported by National Key Research and Development Program of China

National Natural Science Foundation of China

Fostering Funds of Chinese PLA General Hospital for National Excellent Young Scholar Science Fund



Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective treatment regimens for those with relapsed/progressive cHL after single-agent anti-PD-1 are urgently needed. Anti-PD-1 combination with the DNA-demethylating agent decitabine showed positive preliminary results in our test cohort patients who were resistant to anti-PD-1. Here, we assess the efficacy of decitabine plus anti-PD-1 therapy in an expansion cohort and after longer follow-up. We present the response and progression-free survival rates from patients with relapsed/refractory cHL who relapsed/progressed after prior anti-PD-1 monotherapy, and who received decitabine (10 mg/day, days 1–5) plus the anti-PD-1 camrelizumab (200 mg, day 8), every 3 weeks in a phase II trial ( NCT02961101 and NCT03250962). Overall, 51 patients (test cohort: 25, expansion cohort: 26) were treated and 50 evaluated for efficacy. The objective response rate was 52% [nine complete responses (CR); 36%] in the test cohort, and 68% (six CRs; 24%) in the expansion cohort. Median progression-free survival with decitabine plus camrelizumab was 20.0 and 21.6 months, respectively, which was significantly longer than that achieved with prior anti-PD-1 monotherapy. Durable response was observed in an estimated 78% of patients who achieved CR at 24 months. After decitabine plus camrelizumab, the ratio increase of circulating peripheral central memory T cells directly correlated with both clinical response and progression-free survival. Decitabine plus camrelizumab is associated with high response rates and long-term benefits in patients with relapsed/refractory cHL who failed PD-1 inhibitors.

Usage metrics

    Clinical Cancer Research





    Ref. manager